Debra Auguste
Professor, Chemical Engineering
Contact
- d.auguste@northeastern.edu
- 335 ISEC
360 Huntington Avenue
Boston, MA 02115
Office
- 327 ISEC
- 617.373.6243
Lab
- 360 ISEC
Research Focus
Bioresponsive drug delivery; cell and tissue engineering; tissue architecture; targeted therapeutics
About
Joined the Chemical Engineering Department in Fall 2016.
Education
- 2005 PhD in Chemical Engineering, Princeton University
- 1999 SB in Chemical Engineering, MIT
Honors & Awards
- 2022 Outstanding Faculty Service Award
- 2020 American Institute for Medical and Biological Engineering Fellow
- 2018 Biomedical Engineering Society Fellow
- 2012 Presidential Early Career Award in Science and Engineering (PECASE)
- 2012 NIH Director’s New Innovator Award
- 2011 NSF CAREER Award
- 2010 Participant, National Academy of Engineering, Frontiers of Engineering Meeting
- 2010 Named 50 Most Influential African-Americans in Technology
- 2009 DARPA Young Faculty Award
- 2007 Office of Naval Research Young Investigator Program Award
Leadership Positions
- Board of Directors, Biomedical Engineering Society
Professional Affiliations
- American Chemical Society
- American Institute of Chemical Engineers
- Biomedical Engineering Society
- Materials Research Society
Research Overview
Bioresponsive drug delivery; cell and tissue engineering; tissue architecture; targeted therapeutics
Auguste Lab for Bioresponsive Drug Delivery and Tissue Engineering
Our lab engineers solutions to address current challenges in medicine. We design, synthesize, and evaluate new biomaterials that change the way we deliver drugs and cells. These materials exhibit cooperative or heterogeneous features, exemplified in nature.
Department Research Areas
Selected Publications
- P. Guo, J. Yang, D. Liu, L. Huang, G. Fell, J. Huang, M.A. Moses, D.T. Auguste, Dual Complementary Liposomes Inhibit Triple-Negative Breast Tumor Progression and Metastasis, Science Advances, 5(3), 2019, eaav5010
- D.E. Large, J.R. Soucy, J. Hebert, D.T. Auguste, Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery, Advanced Therapeutics, 2018
- P. Guo, D. Liu, K. Subramanyam, B. Wang, J. Yang, J. Huang D.T. Auguste, M.A. Moses, Nanoparticle Elasticity Directs Tumor Uptake, Nature Communications, 9(130), 2018
- D. Liu, D.T. Auguste, Peptide Density Targets and Impedes Triple Negative Breast Cancer Metastasis, Nature Communications, 9, 2018, 2612
- P. Guo, B. Wang, D. Liu, J. Yang, K. Subramanyam, C. McCarthy, J. Hebert, M. Moses, D.T. Auguste, Using Atomic Force Microscopy to Predict Tumor Specificity of ICAM1 Antibody-Directed Nanomedicines, Nano Letters, 18, 2018, 2254-2262
- P. Guo, J. Yang, D. Jia, M.A. Moses, D.T. Auguste, ICAM-1-Targeted, Lcn2 siRNA-Encapsulated Liposomes are Potent Anti-Angiogenic Agents for Triple Negative Breast Cancer, Theranostics, 6, 2016, 1-13
- D. Liu, D.T. Auguste, Cancer Targeted Therapeutics: From Molecules to Drug Delivery Vehicles, Journal of Controlled Release, 219, 2015, 632-643
- B. Wang, P. Guo, D.T. Auguste, Mapping the CXCR4 Receptor on Breast Cancer Cells, Biomaterials, 57, 2015, 161-8
- T.T. Ho, J.O. You, D.T. Auguste, siRNA Delivery Impedes the Temporal Expression of Cytokine-Activated VCAM1 on Endothelial Cells, Annals of Biomedical Engineering, 2015, 1-8
Sep 16, 2022
New Techniques of Treating Breast Cancer
ChE Professor Debra Auguste is developing a new targeted approach to treating triple-negative breast cancer (TNBC) – a form of the disease more prevalent in younger women, with a higher rate of mortality among African American women.
May 18, 2022
Announcing Summer 2022 PEAK Experiences Awardees
Several engineering students and science students mentored by COE faculty are recipients of Northeastern’s Summer 2022 PEAK Experiences Awards.
Apr 15, 2022
Faculty and Staff Awards 2022
Congratulations to all the winners of the faculty and staff awards, and to everyone for their hard work and dedication during the 2021-2022 academic school year.
Oct 12, 2021
Announcing Fall 2021 PEAK Experiences Awardees
Several engineering students and science students mentored by COE faculty are recipients of Northeastern’s Fall 2021 PEAK Experiences Awards. The PEAK Experiences Awards are a progressively structured sequence of opportunities designed to support learners as they continue climbing to new heights of achievement in undergraduate research and creative endeavor throughout their Northeastern journeys. ASCENT AWARDS […]
Apr 20, 2021
FY22 TIER 1 Award Recipients
Congratulations to the 17 COE faculty and affiliates who were recipients of FY22 TIER 1 Interdisciplinary Research Seed Grants for 11 different projects.
Feb 01, 2021
1,000 inspiring Black scientists in America
ChE Assistant Professor Andrew Jones, Professor Debra Auguste, Assistant Professor Eno Ebong, and Solomon Mensah (former PhD student of Eno Ebong) were featured in Cell Mentor’s article of “1,000 inspiring Black scientists in America.”
Mar 27, 2020
Auguste Selected as AIMBE Fellow
ChE Professor Debra Auguste was selected as an American Institute for Medical and Biological Engineering (AIMBE) Fellow in recognition of “her distinguished and continuing achievements in medical and biological engineering”.
Aug 27, 2019
Auguste Awarded Patent for Chemotherapeutic Drug Delivery
ChE Professor Debra Auguste was awarded a patent for “Cationic polymers as co-drugs for chemotherapeutic agents”. Abstract Source: USPTO A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of […]
Apr 03, 2019
Targeting Triple-Negative Breast Cancer
ChE Professor Debra Auguste is collaborating with Boston Children’s Hospital to develop new treatments to target and treat patients with triple-negative breast cancer.
Apr 01, 2019
Auguste Lab Featured on Molecular Pharmaceutics
ChE Professor Debra Auguste’s article on “Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1/FOXM1+ Triple Negative Breast Cancer Cells” published in Molecular Pharmaceutics.